Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | News item

Minimising brolucizumab-related retinal vasculitis, retinal vein occlusion

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has published updated recommendations for minimising the risk of brolucizumab [Pagenax]-related retinal vasculitis and retinal vein occlusion in patients with wet age-related macular regeneration. …
Literatur
Zurück zum Zitat Brolucizumab (Pagenax): Risk of Intraocular Inflammation, Including Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks) Internet Document : 6 Oct 2022. Available from: URL: https://bit.ly/3M8g2oa Brolucizumab (Pagenax): Risk of Intraocular Inflammation, Including Retinal Vasculitis and/or Retinal Vascular Occlusion (Updated Recommendations to Minimise the Known Risks) Internet Document : 6 Oct 2022. Available from: URL: https://​bit.​ly/​3M8g2oa
Metadaten
Titel
Minimising brolucizumab-related retinal vasculitis, retinal vein occlusion
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25269-x

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Multiple drugs

Case report

Antineoplastics

Case report

Secukinumab